Charles Schwab Investment Management Inc. Buys 5,044 Shares of GSK plc (NYSE:GSK)

Charles Schwab Investment Management Inc. grew its holdings in shares of GSK plc (NYSE:GSK) by 4.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,647 shares of the pharmaceutical company’s stock after buying an additional 5,044 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in GSK were worth $4,283,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in GSK. Schechter Investment Advisors LLC boosted its stake in shares of GSK by 15.3% during the 4th quarter. Schechter Investment Advisors LLC now owns 57,320 shares of the pharmaceutical company’s stock worth $1,939,000 after acquiring an additional 7,585 shares during the period. Mission Wealth Management LP increased its holdings in GSK by 17.3% in the 4th quarter. Mission Wealth Management LP now owns 10,518 shares of the pharmaceutical company’s stock worth $356,000 after purchasing an additional 1,555 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in GSK during the 4th quarter worth about $1,136,000. Jones Financial Companies Lllp increased its position in shares of GSK by 28.8% during the fourth quarter. Jones Financial Companies Lllp now owns 72,435 shares of the pharmaceutical company’s stock worth $2,450,000 after buying an additional 16,185 shares during the period. Finally, SRS Capital Advisors Inc. boosted its position in shares of GSK by 51.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,414 shares of the pharmaceutical company’s stock valued at $48,000 after purchasing an additional 480 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on GSK shares. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Trading Down 0.8 %

NYSE:GSK opened at $38.28 on Thursday. The stock’s fifty day moving average price is $37.01 and its two-hundred day moving average price is $36.81. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The company has a market cap of $79.24 billion, a P/E ratio of 24.08, a P/E/G ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.11%. GSK’s dividend payout ratio (DPR) is 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.